Age-Related Eye Disease Study 2 (AREDS2)
NCT00345176 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 4203
Last updated 2015-05-05
Summary
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.
Conditions
- Age-related Macular Degeneration
- Cataract
Interventions
- DIETARY_SUPPLEMENT
-
Lutein/zeaxanthin
10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
- DIETARY_SUPPLEMENT
-
DHA/EPA
Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
- DRUG
-
Lutein/zeaxanthin and DHA/EPA
10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Office of Dietary Supplements (ODS)
collaborator NIH -
National Center for Complementary and Integrative Health (NCCIH)
collaborator NIH -
National Eye Institute (NEI)
lead NIH
Principal Investigators
-
Emily Y Chew, MD · National Eye Institute, National Institutes of Health
-
John Paul SanGiovanni, Sc.D. · National Eye Institute, National Institutes of Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-09-30
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
Antioxidant Systems and Age-Related Macular Degeneration
NCT00668213 ·Status: COMPLETED
-
Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
NCT01653184 ·Status: COMPLETED ·Phase: NA
-
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
NCT01048476 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
NCT01819415 ·Status: COMPLETED ·Phase: NA
-
Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)
NCT01648660 ·Status: COMPLETED ·Phase: NA
-
Age-Related Eye Disease Study (AREDS) Follow-Up
NCT00594672 ·Status: ACTIVE_NOT_RECRUITING
-
Omega-3-fatty Acids on Age-related Macular
NCT01258335 ·Status: COMPLETED ·Phase: NA
-
Lutein for Age-Related Macular Degeneration
NCT00006202 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Trials of Vitamin Supplements and Eye Disease
NCT00000161 ·Status: UNKNOWN ·Phase: PHASE3
-
Effects of Antioxidants on Human Macular Pigments
NCT00718653 ·Status: COMPLETED ·Phase: NA
-
Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)
NCT01527435 ·Status: COMPLETED
-
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
NCT01404845 ·Status: COMPLETED ·Phase: NA
-
Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD
NCT04482465 ·Status: COMPLETED ·Phase: NA
-
The Influence of Lutein Supplements on Age-related Macular Degeneration
NCT01042860 ·Status: COMPLETED ·Phase: NA
-
Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
NCT00987129 ·Status: TERMINATED
-
Effect of Lutein-enriched-egg Beverage on Age-Related Macular Degeneration (AMD)
NCT00902408 ·Status: COMPLETED ·Phase: NA
-
Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00000116 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration
NCT01528605 ·Status: COMPLETED ·Phase: NA
-
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
NCT00060749 ·Status: COMPLETED ·Phase: PHASE1
-
Macular Pigment and Glare Disability
NCT00909090 ·Status: COMPLETED ·Phase: NA
-
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
NCT03478865 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Effect of Eggs and Egg Products on Macular Pigment
NCT00527553 ·Status: COMPLETED ·Phase: NA
-
Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
NCT02264938 ·Status: COMPLETED ·Phase: NA
-
Lutein, Zeaxathin, and Fish Oil Supplementation
NCT06489873 ·Status: RECRUITING ·Phase: NA
-
Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT00346333 ·Status: COMPLETED ·Phase: PHASE3